UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 63.4%

Neg 63.4% Neu 0% Pos 0%

UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.

Comments

No comments yet. Be the first!